Myoferlin is a member of the ferlin family of proteins and is a type 2 transmembrane component originally characterized for its role in membrane fusion during muscle development and repair. Recent research has extended its functional repertoire into oncology, where it is implicated as both a potential biomarker and a driver of aggressive behaviour in multiple tumour types, with particular attention to breast cancer and pancreatic ductal adenocarcinoma (PDAC). Although myoferlin lacks diagnostic specificity as a biomarker, its diverse roles in membrane dynamics and intracellular trafficking make it a candidate therapeutic target.
In cancer cells, myoferlin contributes to the regulation of plasma membrane composition and receptor trafficking. The protein modulates the recycling and stability of receptor tyrosine kinases, thereby sustaining signalling cascades that promote cellular invasion and metastatic behaviour. Myoferlin’s interactions within the endocytic and recycling compartments influence the availability of signalling receptors at the cell surface and affect downstream phenotypes relevant to tumour progression.
The review summarizes physical interactions of myoferlin that are involved in receptor recycling and vesicle trafficking. These interactions connect myoferlin to small GTPases such as RAB proteins and to components of vesicle coat machinery, integrating membrane trafficking with receptor-mediated signalling.
Beyond its roles at the plasma membrane, myoferlin localizes to subcellular compartments that influence mitochondrial biology. It interacts with proteins involved in mitochondrial fusion and participates in the regulation of calcium exchange at the endoplasmic reticulum–mitochondria interface. Through these associations, myoferlin contributes to maintenance of mitochondrial structure and function.
These activities support mitochondrial dynamics that are important for ATP production and metabolic fitness in cancer cells. The review highlights myoferlin’s presence in an interactome that connects ER–mitochondria contacts, calcium handling, and the fusion machinery that together preserve mitochondrial homeostasis.
Experimental reduction or loss of myoferlin disrupts the processes that preserve mitochondrial integrity. Consequences described include mitochondrial fragmentation, decreased ATP production, and a form of iron-dependent cell death. These impairments of bioenergetics and organelle morphology link myoferlin directly to tumour cell survival and metabolic adaptability.
The review emphasizes that targeting myoferlin can negatively affect cancer cell viability through combined effects on signalling receptor availability and on mitochondrial function, creating a dual vulnerability.
Myoferlin also modulates the tumour microenvironment. In PDAC, myoferlin regulates pancreatic cancer-associated fibroblasts (CAFs) and influences the desmoplastic response characteristic of these tumours. Mechanistically, myoferlin interacts with SEC24 to facilitate cargo sorting into coat protein complex II (COPII) vesicles. This interaction supports COPII-mediated transport of the transforming growth factor-beta 1 (TGF-β1) receptor, a pathway that drives CAF activation, extracellular matrix protein deposition, and the dense stromal reaction in PDAC.
Histochemical evidence presented in the review includes comparison of tumours arising in myoferlin-deficient versus wild-type hosts, with alterations in collagen deposition consistent with a role for myoferlin in stromal reprogramming.
The authors propose a therapeutic concept described as a "one punch–two hits" strategy: by inhibiting myoferlin, one could simultaneously disrupt critical metabolic processes within cancer cells (mitochondrial function) and impede pro-tumoural signalling and stromal activation (receptor trafficking and COPII-dependent receptor transport). Targeting myoferlin therefore offers the potential to attack both malignant cells and the supportive stroma.
Preclinical efforts to inhibit myoferlin have focused on small molecules targeting its C2 domains. The review reports that development of such molecules validates the target in experimental models, with evidence that C2 domain inhibitors can reduce tumour growth and metastatic dissemination. Details of specific compounds, dosing, or model systems were not reported within the abstract-level summary of the review.
Figure 1 in the review maps the pivotal role of myoferlin within a cellular interactome, highlighting connections to receptor recycling, mitochondrial calcium dynamics and homeostasis at ER–mitochondria contacts, and COPII-mediated cargo sorting. Figure 2 shows histology from pancreatic tumours developed in myoferlin-deficient versus wild-type mice, stained to visualize collagen fibres and illustrate differences in desmoplasia.
Myoferlin integrates membrane trafficking, receptor stability, mitochondrial homeostasis, and stromal regulation into a coherent pro-tumour program in PDAC and other cancers. Its multifunctional roles make it an attractive therapeutic target, particularly for strategies that aim to exploit combined vulnerabilities of tumour cells and the microenvironment. The review supports continued preclinical development of myoferlin inhibitors, including C2 domain–targeting small molecules, and suggests that further mechanistic and translational work is warranted to determine therapeutic potential and safety. Specific experimental details, clinical trial data, or compound specifications were not provided in the abstract-level material available from the source.